[Myopathy secondary to the treatment with inhibitors of HMG-CoA reductase].
Fuentes
I
I
Institut Català de Farmacologia, CSU Vall d'Hebron, Barcelona.
Aguilera
C
C
D003402:Creatine Kinase / Q000097:blood; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects*; D009135:Muscular Diseases / Q000139:chemically induced* / Q000201:enzymology; D009220:Myositis / Q000139:chemically induced / Q000201:enzymology; D012206:Rhabdomyolysis / Q000139:chemically induced / Q000201:enzymology; D012307:Risk Factors
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D003402:Creatine Kinase